Loading…
AbbVie Inc. is projected to rise to $257.13 by 2027, a +19% move from its current price of $215.40. ABBV is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $213.03 | $215.49 | $217.97 | +0.04% |
| May 30 | $212.11 | $215.57 | $219.09 | +0.08% |
| May 31 | $211.42 | $215.66 | $219.97 | +0.12% |
| Jun 1 | $210.86 | $215.74 | $220.74 | +0.16% |
| Jun 2 | $210.38 | $215.83 | $221.42 | +0.20% |
| Jun 3 | $209.95 | $215.91 | $222.05 | +0.24% |
| Jun 4 | $209.56 | $216.00 | $222.64 | +0.28% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $209.56 | $216.00 | $222.64 | +0.28% |
| Week 2 | $207.52 | $216.60 | $226.07 | +0.56% |
| Week 3 | $206.11 | $217.20 | $228.90 | +0.84% |
| Week 4 | $205.01 | $217.81 | $231.40 | +1.12% |
| Week 5 | $204.11 | $218.41 | $233.71 | +1.40% |
| Week 6 | $203.36 | $219.02 | $235.88 | +1.68% |
| Week 7 | $202.72 | $219.63 | $237.94 | +1.96% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
AbbVie Inc. is a research-based biopharmaceutical company that develops, manufactures, and sells medicines and therapies worldwide. Its portfolio spans autoimmune diseases, inflammatory diseases, cancer, eye care, dermatology, and beyond, including products such as Skyrizi, Rinvoq, Imbruvica, Venclexta, Elahere, Epkinly, Emrelis, and Botox Cosmetic, among others.
The company also offers facial injectables, regenerative medicine, and a range of eye care and gastrointestinal therapies.
ABBV trades at $215.70 per share, reflecting a sizable, multinational healthcare presence. The company ranks 28th by market capitalization, with a market cap of $381.1B. This positioning places it among the leading large-cap healthcare stocks with a broad, diversified revenue base.
A major floor 11.2% below — a decisive break under it would weaken the trend.
The nearest floor, 8.4% below — buyers have tended to step in here.
Price is pressing into resistance (0.1% away) — a breakout level to watch.
A major ceiling 9.7% above — clearing it would confirm fresh momentum.
Key ABBV support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ABBV market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $214.20 | Buy | $214.00 | Buy |
| MA 10 | $212.38 | Buy | $212.28 | Buy |
| MA 20 | $208.99 | Buy | $210.17 | Buy |
| MA 50 | $208.06 | Buy | $210.85 | Buy |
| MA 100 | $216.26 | Sell | $213.82 | Buy |
| MA 200 | $219.39 | Sell | $213.05 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 59.51 | Neutral |
| Stoch RSI (14) | 90.17 | Sell |
| CCI (20) | 116.26 | Buy |
| Williams %R (14) | -2.12 | Info |
| MACD (12,26,9) | 1.12 | Buy |
| ROC (12) | 6.87 | Buy |
| Bollinger %B (20,2) | 0.87 | Neutral |
| Stochastic %K (14) | 97.88 | Sell |
| TRIX (15) | 0.05 | Buy |
| Awesome (5,34) | 6.95 | Buy |
| Ultimate (7,14,28) | 65.46 | Neutral |
| Momentum (10) | 7.54 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 215.58 | Sell |
| ADX (14) | 14.71 | Neutral |
| ATR (14) | 2.28 | Info |
Technically, the sentiment is bullish with an RSI14 of 60. The 50-day simple moving average sits at $208.31, while the 200-day simple moving average sits at $219.23, creating a near-term balance between support and resistance. Immediate support is noted at $197.38, with resistance at $215.70, framing a near-term trading range.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $197.38 | $215.40 | $296.37 | 0% | Neutral | |
| $210.05 | $257.13 | $329.46 | +19% | Neutral | |
| $226.73 | $282.61 | $371.57 | +31% | Bullish | |
| $256.88 | $325.04 | $436.24 | +51% | Bullish | |
| $301.08 | $386.04 | $527.28 | +79% | Bullish | |
| $343.19 | $445.34 | $617.77 | +107% | Bullish | |
| $361.66 | $474.57 | $667.56 | +120% | Bullish | |
| $392.31 | $520.17 | $741.08 | +141% | Bullish | |
| $414.03 | $554.39 | $799.19 | +157% | Bullish | |
| $413.75 | $559.24 | $815.08 | +160% | Bullish | |
| $631.69 | $890.35 | $1,359.49 | +313% | Bullish | |
| $1,199.39 | $1,812.78 | $2,966.20 | +742% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $197.38 | $215.40 | $252.75 | +0.00% |
| June 2026 | $190.38 | $222.09 | $264.11 | +3.11% |
| July 2026 | $190.35 | $223.34 | $268.10 | +0.56% |
| August 2026 | $190.78 | $224.85 | $271.88 | +0.68% |
| September 2026 | $197.13 | $233.19 | $283.64 | +3.71% |
| October 2026 | $201.85 | $239.59 | $293.00 | +2.74% |
| November 2026 | $200.41 | $238.59 | $293.15 | -0.42% |
| December 2026 | $201.13 | $240.14 | $296.37 | +0.65% |
Click any year to see its month-by-month ABBV forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect ABBV to range from $197.38 to $296.37 through 2026. The $215.40 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The ABBV price prediction for 2027 points to an average of $257.13 (low $210.05, high $329.46) — a potential gain of +19% on today's $215.40. A consolidation phase looks the most probable path here.
In 2028, ABBV is projected to trade between $226.73 and $371.57, averaging $282.61 — a potential gain of +31% from today's $215.40. That is up +10% on the projected 2027 average. Momentum favours further upside here.
AbbVie Inc.'s 2029 outlook centres on $325.04, within a $256.88 to $436.24 range. That is up +15% on the projected 2028 average. That marks a +51% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, ABBV could reach as high as $527.28, with a base case around $386.04 and support toward $301.08 — roughly +79% from $215.40. Momentum favours further upside here.
Expect ABBV to range from $343.19 to $617.77 through 2031. The $445.34 average target implies a +107% move from current prices. That is up +15% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The ABBV price prediction for 2032 points to an average of $474.57 (low $361.66, high $667.56) — a potential gain of +120% on today's $215.40. Momentum favours further upside here.
In 2033, ABBV is projected to trade between $392.31 and $741.08, averaging $520.17 — a potential gain of +141% from today's $215.40. That is up +10% on the projected 2032 average. Buyers look set to stay in control over this stretch.
AbbVie Inc.'s 2034 outlook centres on $554.39, within a $414.03 to $799.19 range. That is up +7% on the projected 2033 average. That marks a +157% change versus current levels. Momentum favours further upside here.
By 2035, ABBV could reach as high as $815.08, with a base case around $559.24 and support toward $413.75 — roughly +160% from $215.40. Buyers look set to stay in control over this stretch.
Expect ABBV to range from $631.69 to $1,359.49 through 2040. The $890.35 average target implies a +313% move from current prices. That is up +59% on the projected 2035 average. Momentum favours further upside here.
The ABBV price prediction for 2050 points to an average of $1,812.78 (low $1,199.39, high $2,966.20) — a potential gain of +742% on today's $215.40. Buyers look set to stay in control over this stretch.
Investing $1,000 in ABBV today (≈ 4.642526 ABBV) could be worth
$8,415.89
+$7,415.89 (+742%) by 2050 · US Dollar
Based on the average projected ABBV price of $1,812.78 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ABBVwould be worth at today's price.
$1,000 invested in ABBV on May 27, 2025 (≈ 5.38445 ABBV) would be worth
$1,159.81
+$159.81 (+16.0%) today · 1.16× · US Dollar
Based on a ABBV entry price of $185.72 vs. today's $215.4.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $212.3 | $1,014.6 | +1.5% |
| 1 month ago | $197.38 | $1,091.3 | +9.1% |
| 3 months ago | $224.69 | $958.65 | -4.1% |
| 6 months ago | $227.7 | $945.98 | -5.4% |
| 1 year ago | $185.72 | $1,159.81 | +16.0% |
| All time (5.0y) ago | $112.21 | $1,919.62 | +92.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ABBV forecast.
Our base-case forecast reaches $430.00 around 2031.
Implied market cap at $430.00: $759.72B
The year-by-year forecast shows a strong multi-year uptrend. In 2026, the average target is $215.70 with a projected price range around the current level. By 2030, the average target rises to $380.39 with a 76.3% ROI, and the outlook remains bullish through 2035.
The forecast envisions substantial gains by 2040 (average $863.03, ROI 300.1%) and by 2050 (average $1,752.35, ROI 712.4%), signaling a broad, long-term appreciation path despite inherent uncertainty. These are estimates and not guarantees, with risks and market conditions affecting outcomes.
Tap a question to reveal the answer.
According to the forecast, ABBV’s average price in 2030 is $380.39 with an ROI of 76.3%, and the sentiment for 2030 is BULLISH.
The forecast shows a bullish trajectory from 2027 onward, with 2027 average $256.18 (ROI 18.8%) and rising to 2029 average $323.12 (ROI 49.8%), continuing higher through 2035 and beyond, though these are estimates and carry uncertainty.
Yes. The forecast shows 2027 max at $328.38 and 2028 max at $367.75, with 2029 max at $433.78, indicating the price could exceed $300 in the near term.
ABBV’s current price is $215.70, and its market capitalization is $381.1B.
The 30-day technical picture is bullish, with RSI14 at 60. The 30-day range runs from $199.71 to $232.97, there is support at $197.38 and resistance at $215.70.
AbbVie Inc. Community Discussion
0Share your AbbVie Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.